Research programme: antimalarials - Medicines for Malaria Venture/Merck
Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in USA (PO)
- 18 Apr 2009 Preclinical trials in Malaria in USA (PO)